albuterol / budesonide vs fluticasone furoate/umeclidinium/vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanisms: Beta-2 adrenergic receptor · Glucocorticoid receptor · full Asthma pipeline

albuterol / budesonide · Airsupra

Marketed by AstraZeneca

Approved in Asthmacombination (SABA + ICS)
Reliable signal

NCT03769090 · Phase 3 · completed

Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).

Next expected readout: February 2027 · NCT06422689 (registry estimate)

Reported efficacy

Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212 (met)

Result source: NCT05505734

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT02924688 · Phase 3 · completed

This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.

Next expected readout: January 2027 · NCT05757102 (registry estimate)

Reported efficacy

Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)

Result source: NCT02924688

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointalbuterol /​ budesonidefluticasone furoate/​umeclidinium/​vilanterol
Severe exacerbations, annualised rate0.5 vs 0.6vs AS MDI80/180 μg · n 1054NCT03769090
2 other results
  • 0.1 vs 0.3 160/180 μg · n 1209 · Phase 3 · secondary NCT05505734
  • 0.1 vs 0.3 160/180 μg · n 1180 · Phase 3 · secondary NCT05505734
—Trial running · NCT04651777
Trough FEV1, change0.1 vs 0.0+0.1 vs placebo160/180 μg · wk 12 · n 197NCT03847896
3 other results
  • 0.1 vs 0.0 80/180 μg · wk 12 · n 198 · Phase 3 · primary NCT03847896
  • 0.1 vs 0.0 160/180 μg · wk 1 · n 197 · Phase 3 · secondary NCT03847896
  • 0.1 vs 0.0 80/180 μg · wk 1 · n 198 · Phase 3 · secondary NCT03847896
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
ACQ-5, change—Not posted · NCT06502366—Trial running · NCT04651777
OCS dose reduction—Not posted · NCT06502366—Trial running · NCT04651777

Severe exacerbations, annualised rate

albuterol /​ budesonide
0.5 vs 0.6vs AS MDI80/180 μg · n 1054NCT03769090
2 other results
  • 0.1 vs 0.3 160/180 μg · n 1209 · Phase 3 · secondary NCT05505734
  • 0.1 vs 0.3 160/180 μg · n 1180 · Phase 3 · secondary NCT05505734
fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777

Trough FEV1, change

albuterol /​ budesonide
0.1 vs 0.0+0.1 vs placebo160/180 μg · wk 12 · n 197NCT03847896
3 other results
  • 0.1 vs 0.0 80/180 μg · wk 12 · n 198 · Phase 3 · primary NCT03847896
  • 0.1 vs 0.0 160/180 μg · wk 1 · n 197 · Phase 3 · secondary NCT03847896
  • 0.1 vs 0.0 80/180 μg · wk 1 · n 198 · Phase 3 · secondary NCT03847896
fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387

ACQ-5, change

albuterol /​ budesonide
—Not posted · NCT06502366
fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777

OCS dose reduction

albuterol /​ budesonide
—Not posted · NCT06502366
fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. albuterol / budesonide: 4 of 4 rows · fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricalbuterol /​ budesonidefluticasone furoate/​umeclidinium/​vilanterol
Dropout rate
9.9%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
11.7%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
28.2%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
3.6%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
7.8%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
—160/180
NCT06245551 · Phase 3
—
NCT05555290 · Phase 3 · registry result, not featured evidence
—
NCT04234464 · Phase 3 · registry result, not featured evidence
—160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
7.7%100/31.25/25 mcgb
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
11.1%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
7.3%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
Discontinued due to AEs
0.7%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
0.7%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
0.5%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
1%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
0.5%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
—160/180
NCT06245551 · Phase 3
—
NCT05555290 · Phase 3 · registry result, not featured evidence
—
NCT04234464 · Phase 3 · registry result, not featured evidence
—160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
0.7%100/31.25/25 mcgb
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
1.8%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
Serious AEs
5.2%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
3.8%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
3.1%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
1%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
2%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
0%160/180
NCT06245551 · Phase 3
0%
NCT05555290 · Phase 3 · registry result, not featured evidence
0%
NCT04234464 · Phase 3 · registry result, not featured evidence
0%160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
4.4%100/31.25/25 mcgb
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
3.6%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
Most frequent reported AEs
160/180 μga
nasopharyngitis 7.5%
headache 4.3%
covid-19 3.3%
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
80/180 μg
nasopharyngitis 5.8%
headache 4.7%
covid-19 4.5%
NCT03769090 · Phase 3 · Asthma · phase 3
160/180 μg
upper respiratory tract infection 5.4%
covid-19 5.1%
nasopharyngitis 3.7%
NCT05505734 · Phase 3 · Asthma · phase 3
160/180 μg
nasopharyngitis 7.6% (placebo 5.5%)
headache 5.1% (placebo 7%)
dysphonia 2% (placebo 0%)
NCT03847896 · Phase 3 · Asthma · phase 3
80/180 μg
nasopharyngitis 6.4% (placebo 5.5%)
headache 4.9% (placebo 7%)
upper respiratory tract infection 1.5% (placebo 1%)
NCT03847896 · Phase 3 · Asthma · phase 3
160/180
bronchial irritation 1.6% (placebo 0%)
diarrhoea 0% (placebo 1.6%)
headache 0% (placebo 1.6%)
NCT06245551 · Phase 3
anxiety 1%
cough 1%
covid-19 1%
NCT05555290 · Phase 3 · registry result, not featured evidence
anxiety 0% (placebo 1.7%)
dyspnoea 0% (placebo 1.7%)
NCT04234464 · Phase 3 · registry result, not featured evidence
160/180 μg
miliaria 0%
NCT04848662 · Phase 1 · registry result, not featured evidence
100/31.25/25 mcgb
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
FF 200 ug, UMEC 62.5 ug, VI 25 ug
covid-19 5.7%
nasopharyngitis 4.5%
upper respiratory tract infection 4.5%
NCT04937387 · Phase 3 · Asthma · phase 3
FF 100 ug, UMEC 62.5 ug, VI 25 ug
upper respiratory tract infection 7.8%
covid-19 3.3%
nasopharyngitis 3.3%
NCT04937387 · Phase 3 · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 27.7%
pharyngitis 10.6%
bronchitis 8.5%
NCT03184987 · Phase 3 · combination
100/62.5/25 mcg to 200/62.5/25 mcg
bronchitis 22.2%
dysgeusia 22.2%
nasopharyngitis 22.2%
NCT03184987 · Phase 3 · combination
200/62.5/25 mcg
nasopharyngitis 32.7%
dysgeusia 10.9%
eczema 9.1%
NCT03184987 · Phase 3 · combination

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.
  2. bPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

albuterol / budesonide

Severe Exacerbation 22.9% (n=1054) vs 26.2% (n=1014) AS MDI80/180 μg
event rate · % of participants
NCT03769090 · Phase 3 · Asthma · phase 3 · converted to % from 241 Participants as posted
Severe Exacerbation Rate Annualized 0.49 vs 0.59 AS MDI per year80/180 μg
event rate · per year
NCT03769090 · Phase 3 · Asthma · phase 3
show 2 more results
0.15 vs 0.32 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
0.15 vs 0.33 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
ACQ-5 64.7% (n=1052) vs 62.1% (n=1014) AS MDI @ 24wk80/180 μg
responder rate · % of participants
NCT03769090 · Phase 3 · Asthma · phase 3 · converted to % from 681 Participants as posted
Time to First Severe Exacerbation 5.1% (n=1209) vs 9.1% (n=1212) PT007160/180 μg
event count · % of participants
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 62 Participants as posted
show 3 more results
5.3% (n=1209) vs 9.4% (n=1212) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 64 Participants as posted
6% (n=1180) vs 10.7% (n=1173) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 71 Participants as posted
6.2% (n=1180) vs 11.2% (n=1173) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 73 Participants as posted
Total Systemic Glucocorticoid Exposure mg Per 23.2 vs 61.9 PT007 per year160/180 μg
absolute value · per year
NCT05505734 · Phase 3 · Asthma · phase 3
show 1 more result
23 vs 63 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
Total Systemic Glucocorticoid Duration 0.01 vs 0.03 PT007 months160/180 μg
absolute value · months
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to months from 0.4 days as posted
show 1 more result
0.01 vs 0.03 PT007 months*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to months from 0.4 days as posted
FEV1 AUC0-6 0.259 vs 0.097 placebo L @ 12wk160/180 μg
absolute change · L
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 258.6 mL as posted
show 1 more result
0.242 vs 0.097 placebo L @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 242.2 mL as posted
Time to FEV1 15 Increase 7.5 vs 14 placebo minutes @ 0wk160/180 μg
absolute value · minutes
NCT03847896 · Phase 3 · Asthma · phase 3
show 1 more result
7 vs 14 placebo minutes @ 0wk80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
Duration of FEV1 15 Increase 185.5 vs 229.5 placebo minutes @ 0wk160/180 μg
absolute value · minutes
NCT03847896 · Phase 3 · Asthma · phase 3
show 1 more result
174 vs 229.5 placebo minutes @ 0wk80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
ACQ-7 66.5% (n=161) vs 55.3% (n=159) placebo @ 12wk160/180 μg
responder rate · % of participants
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to % from 107 Participants as posted
show 1 more result
65.5% (n=165) vs 55.3% (n=159) placebo @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to % from 108 Participants as posted
FEV1 Max Fall 6.95% (n=64) vs 24.46% (n=64) placebo160/180
absolute value · percentage points
All subjects
NCT06245551 · Phase 3
FEV1 Max Fall LT 10 75% (n=64) vs 3.1% (n=64) placebo160/180
event count · % of participants
Maximum percentage fall <10%
NCT06245551 · Phase 3 · converted to % from 48 Participants as posted

+ 12 further endpoints in the CSV export.

fluticasone furoate/umeclidinium/vilanterol

FEV1 Change 3 h 0.22 vs 0.132 FF/VI L @ 24wk100/31.25/25 mcg
absolute change · L
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 3 more results
0.256 vs 0.132 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.243 vs 0.132 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.286 vs 0.132 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
ACQ-7 -0.814 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 ug
absolute change · score
NCT04937387 · Phase 3 · Asthma · phase 3
show 1 more result
-0.968 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · fluticasone furoate/umeclidinium/vilanterol's landscape